Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport IP professionals need biosequence search & patent legal status. Patsnap Eureka Life Science unifies both for FTO, prior art, and defensible IP opinions. Book a demo.
Article | Rapport Accelerate your Markush structure patent search from weeks to hours with Patsnap Eureka Life Science. Leverage AI-powered extraction, analysis, and monitoring for IP insights. Book a demo.
Article | Rapport How does tezepelumab's TSLP inhibition differ from IL-33 blockade (itepekimab, astegolimab) in phenotype coverage, clinical efficacy, and atopic march pipeline potential?
Article | Rapport APOE ε4 genotype ARIA risk multipliers and clinical decision framework for lecanemab and donanemab prescribing in Alzheimer's disease treatment.
Article | Rapport How do FXIa inhibitors asundexian and milvexian compare to apixaban and rivaroxaban on bleeding risk and efficacy? Patent and clinical trial evidence analysed.
Article | Rapport Head-to-head analysis of lecanemab, donanemab, and aducanumab across mechanism, Phase III efficacy, ARIA safety, dosing regimens, and clinical applicability.
Article | Rapport How do Tarlatamab and Elranatamab differ from gamma-delta T-cell therapies in TME penetration, cytokine release risk, and MHC-I resistance? A mechanistic analysis.
Article | Rapport How do patient population differences and I² heterogeneity (0%–95%) across five Lecanemab/Donanemab trials affect meta-analysis reliability and clinical applicability?
Article | Rapport A multi-dimensional safety analysis of lecanemab and donanemab ARIA risk data: RR 4.35 overall, APOE ε4 genotype stratification, and CNS superficial siderosis.
Article | Rapport How do FXR agonists, THRβ agonists, and ACC inhibitors differ in targeting MASH? Mechanistic analysis and pipeline combination strategy evidence.
Article | Rapport Meta-analysis comparing lecanemab and donanemab vs placebo across ADCOMS, CDR-SB, ADAS-Cog 14, and amyloid PET in early Alzheimer's disease. Full effect sizes, CIs, and heterogeneity data.
Article | Rapport DESTINY-Breast04's updated 32-month follow-up confirms T-DXd's OS and PFS benefit in HER2-low mBC, with key findings on ILD safety, ER-low subgroups, and ADC positioning.
Article | Rapport How voclosporin and sparsentan differ from cyclosporine in IgA nephropathy and FSGS — patent-disclosed structures, selectivity, and reduced nephrotoxicity explained.
Article | Rapport Analyse THRβ agonist selectivity SAR, hepatic uptake optimisation, ADME/PK profiles, and structural strategies that reduce cardiac and bone off-target effects vs non-selective THR agonists.
Article | Rapport DESTINY-Breast04 PFS2 data reveals T-DXd preserves sensitivity to subsequent therapies. Discover optimal T-DXd sequencing for HER2-low metastatic breast cancer.